World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
39248
World Ranking
15868
National Ranking
1459

Matthew R. Sydes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Matthew R. Sydes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 440 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Matthew R. Sydes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Matthew R. Sydes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Matthew R. Sydes is affiliated with University College London in the United Kingdom and focuses primarily on medicine. Their research portfolio includes 252 publications in the broad field of medicine with notable contributions to several subfields. These subfields include Pulmonary and Respiratory Medicine, Statistics and Probability, Economics and Econometrics, Radiology, Nuclear Medicine and Imaging, as well as Public Health, Environmental and Occupational Health.

The main topics of Matthew R. Sydes' work highlight a concentration on prostate cancer and clinical trials. These topics consist of:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • Ethics in Clinical Research
  • Radiopharmaceutical Chemistry and Applications
  • Meta-analysis and systematic reviews

Their recent significant publications illustrate active engagement in prostate cancer research, including studies published in leading journals such as The Lancet and European Urology. Notable papers include:

  • The Lancet Commission on prostate cancer: planning for the surge in cases, 2024, The Lancet
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial, 2020, The Lancet
  • Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data, 2020, The Lancet
  • Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer, 2021, JAMA Oncology

Matthew R. Sydes has collaborated frequently with several researchers, including:

  • Nicholas D. James
  • Noel W. Clarke
  • Mahesh Parmar
  • Gerhardt Attard
  • David P. Dearnaley

Their work has appeared often in specific publication venues. These journals reflect the scientific communities where their research is circulated and referenced:

  • Trials
  • Annals of Oncology
  • European Urology
  • Journal of Clinical Oncology
  • The Lancet

Best Publications

  • Practical methods for incorporating summary time-to-event data into meta-analysis

    Jayne F Tierney;Lesley A Stewart;Davina Ghersi;Sarah Burdett

  • Patient survival after D-1 and D-2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

    A Cuschieri;S Weeden;J Fielding;J Bancewicz

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.

    Gillian C. Barnett;Gillian C. Barnett;Charlotte E. Coles;Rebecca M. Elliott;Caroline Baynes

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird

  • Adaptive designs in clinical trials: why use them, and how to run and report them

    Philip Pallmann;Alun W. Bedding;Babak Choodari-Oskooei;Munyaradzi Dimairo

  • Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

    Padraig Warde;Malcolm David Mason;Keyue Ding;Peter Kirkbride

  • High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

    Harry C. Schouten;Wendi Qian;Stein Kvaloy;Adolfo Porcellini

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

    David P Dearnaley;David P Dearnaley;Gordana Jovic;Isabel Syndikus;Vincent Khoo

  • Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

    Nicholas David James;Melissa R. Spears;Noel W. Clarke;David P. Dearnaley

  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Claire L. Vale;Sarah Burdett;Larysa H. M. Rydzewska;Laurence Albiges

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

    Ian J. Lewis;Marianne A. Nooij;Jeremy Whelan;Matthew R. Sydes

  • Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    Wanling Xie;Meredith M. Regan;Marc Buyse;Susan Halabi

  • An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study

    G. M. Mead;M. R. Sydes;J. Walewski;A. Grigg

Frequent Co-Authors

David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Nicholas D. James
Nicholas D. James Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Malcolm David Mason
Malcolm David Mason Cardiff University
Chris Parker
Chris Parker Institute of Cancer Research
Mahesh K. B. Parmar
Mahesh K. B. Parmar University College London
Silke Gillessen
Silke Gillessen Universita della Svizzera Italiana
Gerhardt Attard
Gerhardt Attard University College London
George N. Thalmann
George N. Thalmann University of Bern
Pancras C.W. Hogendoorn
Pancras C.W. Hogendoorn Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a range of related online degrees and flexible career options. Many students consider roles beyond clinical practice, such as healthcare management or specialized nursing. For aspiring leaders, pursuing a healthcare administration degree online offers a fast-tracked route into hospital or clinic management, focusing on policy, finance, and leadership.

Nurses looking to expand their roles can benefit from flexible adn to fnp programs, bridging the gap from Associate Degree in Nursing to Family Nurse Practitioner. Those interested in holistic health may consider accredited nutrition degrees online, which prepare graduates for careers in dietetics, wellness coaching, and community health.

If you aspire to administration at the highest level, look for top cahme accredited mha programs that emphasize advanced leadership, healthcare policy, and organizational management. With online options, you can gain relevant skills to thrive in a dynamic healthcare environment alongside traditional medical studies.

Best Scientists Citing Matthew R. Sydes

Trending Scientists

Recently Published Articles